News | Cardio-oncology | January 03, 2019

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

Study finds heart drug carvedilol reduces major cardiac side effects of breast cancer treatment

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab

January 3, 2019 — Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a study presented recently at EuroEcho-Imaging 2018, Dec. 5-8 in Milan, Italy.1

“Heart damage is a major side effect of the breast cancer drug trastuzumab and may force patients to stop treatment,” said lead author Maryam Moshkani Farahani, M.D., associate professor, Baqiyatallah University of Medical Sciences, Tehran, Iran. “Our study suggests that patients who take the beta-blocker carvedilol together with trastuzumab have less heart damage than those who take trastuzumab alone.”

The study enrolled 71 patients with non-metastatic HER2-positive breast cancer. Patients were randomly allocated to receive trastuzumab with, or without, carvedilol.

Impaired function of the heart’s left ventricle is the main type of heart damage caused by trastuzumab. Carvedilol is used to treat patients with impaired left ventricular function after a heart attack. It is also prescribed for heart failure and high blood pressure.

For the study, an imaging technique called two-dimensional speckle tracking echocardiography was used to assess the systolic and diastolic function of the left ventricle initially and at three months. Specifically, systolic function was measured using global longitudinal strain and strain rate, while diastolic function was assessed with strain rate.

According to all of the measurements, systolic and diastolic left ventricular function were better preserved at three months in patients who took carvedilol with trastuzumab compared to those who took trastuzumab alone.

The pumping function of the heart (left ventricular ejection fraction) did not differ between treatment groups at the start of the study or at three months. “The measures we used to assess left ventricular function – namely global longitudinal strain and strain rate – are more sensitive than left ventricular ejection fraction,” explained Moshkani Farahani.

She noted that carvedilol can cause side effects, such as dizziness, drowsiness, fainting, mood changes, shortness of breath and diarrhoea. Patients who feel unwell when taking the medication should consult their doctor.

Moshkani Farahani concluded: “The findings indicate that carvedilol may be an effective way to prevent the heart damage caused by trastuzumab treatment. We now advise our patients with non-metastatic HER2-positive breast cancer to take prophylactic carvedilol, but a larger study is needed before firm recommendations can be made.”

For more information: www.escardio.org

 

Reference

1. Moshkani Farahani M., Nourian S. Assessment of treatment with Carvedilol in preventing early stage left ventricular dysfunction in breast cancer patients by 2D speckle tracking echocardiography. Presented at EuroEcho-Imaging, Dec. 5, 2018.

Related Content

Test selection should be a shared decision between patient and physician rather than directed by insurers’ test substitution policies, according to a statement published online in the Journal of the American College of Cardiology.[1] The statement summarizes the proceedings of a recent summit convened by the American Society of Nuclear Cardiology (ASNC), leadership of the American College of Cardiology Imaging Council, American Society of Echocardiography (ASE), Society of Cardiovascular Computed Tomography
News | Cardiac Imaging | September 22, 2021
September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by
A comparison of color-flow Doppler cardiac ultrasound showing blood flow, and blood speckle tracking revealing a more detailed and complex understanding of the low. It shows the formation of a vortex that may play a role in future assessments for the efficiency of flow in the heart and vessels. #ASE21 #ASE2021 #Vectorflowimaging

A comparison of color-flow Doppler cardiac ultrasound showing blood flow, and blood speckle tracking revealing a more detailed and complex understanding of the flow. It shows the formation of a vortex that may play a role in future assessments for the efficiency of flow in the heart and vessels. Image from JASE, read more.

Feature | Cardiac Imaging | August 17, 2021 | By Dave Fornell, Editor
In the past several years, a few ca...
A cardiac MRI of athletes who had COVID-19 is seven times more effective in detecting inflammation of the heart than symptom-based testing, according to a study led by researchers at The Ohio State University Wexner Medical Center and College of Medicine with 12 other Big Ten programs.

Cardiac Magnetic Resonance Imaging in Athletes With Clinical and Subclinical Myocarditis A-D, Athlete A with subclinical possible myocarditis was asymptomatic with normal electrocardiogram (ECG), echocardiogram, and high-sensitivity troponin findings. A, T2 mapping showing elevated T2 in basal-mid inferolateral wall in short axis view. B, late gadolinium enhancement (LGE) in the basal inferolateral wall in short axis view. C, Postcontrast steady state-free precession (SSFP) images showing contrast uptake in the basal-mid inferolateral wall in short axis view. D, LGE in the inferolateral wall in 3-chamber view. E-H, Athlete B with subclinical probable myocarditis was asymptomatic with normal ECG, normal echocardiogram, and elevated high-sensitivity troponin findings. E, T2 mapping showing elevated T2 in the anteroseptal wall in short axis view. F, LGE in the anteroseptal wall in 3-chamber view. G, T2 mapping showing elevated T2 in the anteroseptal wall in 3-chamber view. F, Postcontrast SSFP image showing pericardial effusion in short axis view. I-K, Athlete C with clinical myocarditis and chest pain, dyspnea, abnormal ECG, normal echocardiogram, and normal troponin findings. I, T2 mapping showing elevated T2 in the lateral wall short axis view. J, Postcontrast SSFP images showing contrast uptake in midlateral wall in short axis view. K, LGE in the epicardial midlateral wall in short axis view. L-N, Athlete D with clinical myocarditis, chest pain, abnormal ECG, echocardiogram, and troponin findings. L, T1 mapping showing elevated native T1 in midlateral wall in short axis view. M, T2 mapping showing elevated T2 in the midlateral wall in short axis view. N, LGE in the epicardial midlateral wall in short axis view. IR indicates inferior right view; IRP, inferior, right, posterior view; PLI, posterior, left, inferior view; SL, superior left view; SLA, superior, left, anterior view. Image courtesy of JAMA Cardiol. Published online May 27, 2021. doi:10.1001/jamacardio.2021.2065

News | Cardiac Imaging | June 15, 2021
June 15, 2021 — A...
Rensselaer algorithm can identify risk of cardiovascular disease using lung cancer scan #CT
News | Cardiac Imaging | June 14, 2021
June 14, 2021 — Heart disease and cancer are the ...
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | November 17, 2020
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many wome
An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

An example of a CT coronary artery calcium scoring exam showing how each vessel segment is scored to assess a patient's risk for a future heart attack. Example is from Philips Healthcare.

News | Cardiac Imaging | September 25, 2020
September 25, 2020 — A study out of University Hospitals (UH) found that removing the cost barrier for coronary arter
Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.